EP2538925
APIXABAN samsetningar
Status:
EP Einkaleyfi ógilt eftir andmæliEP appl. date:
24.2.2011EP published:
16.12.2015EP application number:
11707284.3
EP translation filed:
2.2.2016Grant published:
15.2.2016EPO information:
European Patent Register
Max expiry date:
23.2.2031Expiry date:
23.2.2022
Title:
APIXABAN FORMULATIONS
Timeline
Today
24.2.2011EP application
16.12.2015EP Publication
2.2.2016Translation submitted
15.2.2016Registration published
23.2.2022Expires
Owner
Name:
Bristol-Myers Squibb Holdings Ireland Unlimited CompanyAddress:
Hinterbergstrasse 16, 6312, Steinhausen, , CH
Name:
Pfizer Inc.Address:
235 East 42nd Street, 10017, New York, NY, US
Inventor
Name:
PATEL, JatinAddress:
Princeton, NJ, US
Name:
FROST, CharlesAddress:
Princeton, NJ, US
Name:
JIA, JingpinAddress:
Princeton, NJ, US
Name:
VEMA-VARAPU, ChandraAddress:
Princeton, NJ, US
Agent
Name:
Örn Þór slf.Address:
Klukkuvöllum 17, 221, Hafnarfirði,
Priority
Number:
308056 PDate:
25.2.2010Country:
US
Classification
Categories:
A61K 9/28, A61K 9/48, A61K 31/437, A61P 7/02
Annual fees
Number
Paid
Expires
Payer
Number: 6
Paid: 15.2.2016
Expires: 23.2.2017
Payer: Árnason Faktor
Number: 7
Paid: 9.1.2017
Expires: 23.2.2018
Payer: Árnason Faktor
Number: 8
Paid: 8.1.2018
Expires: 23.2.2019
Payer: Árnason Faktor
Number: 9
Paid: 9.1.2019
Expires: 23.2.2020
Payer: Árnason Faktor
Number: 10
Paid: 14.1.2020
Expires: 23.2.2021
Payer: Árnason Faktor ehf.
Number: 11
Paid: 12.1.2021
Expires: 23.2.2022
Payer: Árnason Faktor ehf.